Brands in demand: Keytruda, Dupixent and Ozempic lead 2023 new sales predictions — Evaluate report
What’s old is new again for 2023 when it comes to pharma drug brands added sales this year. Led by Merck’s Keytruda and Sanofi and Regeneron’s Dupixent, the biggest new sales generators are mostly from already established drugs, according to Evaluate Pharma’s annual forecast.
Only two of the top 10 on the list are new 2022 FDA approvals — Eli Lilly’s Mounjaro at No. 4 and Novo Nordisk’s Wegovy at No. 6.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.